Lipid-lowering trials in diabetes.

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Diseases

Background:

• Type 2 diabetes is a significant risk factor for coronary heart disease (CHD).
• Metabolic syndrome and diabetes are highlighted by the National Cholesterol Education Program's Adult Treatment Panel III.
• Diabetes is considered a CHD risk equivalent, necessitating specific therapeutic considerations.

Purpose of the Study:

• To evaluate the efficacy of lipid-lowering therapy in preventing coronary atherosclerosis progression in diabetic patients.
• To address the gap in clinical trial data regarding primary prevention of CHD in individuals with type 2 diabetes.
• To report findings from the Diabetes Atherosclerosis Intervention Study (DAIS).

Main Methods:

• The study involved a large lipid-lowering trial focused on coronary atherosclerosis in a specific diabetic population.
• Participants received fenofibrate therapy.
• Coronary atherosclerosis progression was assessed using quantitative coronary angiography.

Main Results:

• Fenofibrate therapy was associated with a reduced progression of coronary atherosclerosis.
• The Diabetes Atherosclerosis Intervention Study (DAIS) provided the first report from a major lipid-lowering trial in this specific context.
• Findings suggest potential benefits of fenofibrate in managing cardiovascular risk in type 2 diabetes.

Conclusions:

• Fenofibrate therapy demonstrated a positive effect on coronary atherosclerosis progression in patients with type 2 diabetes.
• The DAIS trial contributes valuable data to the primary prevention of CHD in diabetic populations.
• Further research and ongoing trials are crucial to solidify these findings and inform clinical practice.